Continuous glucose monitoring during late pregnancy and after delivery for gestational diabetes
Pregnancy and Postpartum Continuous Glucose Monitoring in Gestational Diabetes
This study will collect Dexcom G7 glucose data from people with gestational diabetes during the third trimester and for two weeks after birth to see if those patterns predict an abnormal 6‑week postpartum oral glucose tolerance test.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT07174245 on ClinicalTrials.gov |
What this trial studies
Pregnant people with a diagnosis of gestational diabetes who are prescribed a Dexcom G7 will continue using their device during the third trimester and wear one sensor for up to 14 days postpartum. Researchers will analyze CGM glucose patterns and compare them to each participant's standard-of-care 6‑week postpartum oral glucose tolerance test result and a remote questionnaire. This is an observational protocol with no experimental treatments, and clinical care remains under the participant's usual providers. The aim is to find glucose pattern predictors of abnormal postpartum glucose tolerance.
Who should consider this trial
Good fit: Adults (age 18+) with a current diagnosis of gestational diabetes who are prescribed and using a Dexcom G7 are ideal candidates.
Not a fit: People with pregestational diabetes, those not using a Dexcom device, those with adhesive allergies preventing CGM use, or those on chronic oral steroids are unlikely to qualify or benefit from this specific protocol.
Why it matters
Potential benefit: If successful, this approach could help identify patients at higher risk of persistent abnormal blood sugar after pregnancy so follow-up and interventions can be targeted sooner.
How similar studies have performed: CGM has been used in pregnancy to track glucose and guide management, but applying third‑trimester and immediate postpartum CGM data specifically to predict 6‑week OGTT results is a relatively new and only preliminarily studied approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of gestational diabetes during current pregnancy * age 18 or older * prescribed Dexcom G7 Exclusion Criteria: * Pregestational diabetes * known skin adhesive allergy which inhibits ongoing use of CGM * chronic oral steroid use.
Where this trial is running
New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Grenye O'Malley, MD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Shaziah Hassan
- Email: shaziah.hassan@mssm.edu
- Phone: 212-241-5355
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.